• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    COVID-19 drug-induced liver injury: A recent update of the literature

    2022-12-09 02:52:12LekhaSahaSoumyaVijKajalRawat
    World Journal of Gastroenterology 2022年45期

    Lekha Saha, Soumya Vij, Kajal Rawat

    Abstract The severity of coronavirus disease 2019 (COVID-19) may be correlated with the risk of liver injury development. An increasing number of studies indicate that degrees of hepatotoxicity have been associated with using some medications in the management of COVID-19 patients. However, limited studies have systematically investigated the evidence of drug-induced liver injury (DILI) in COVID-19 patients. An increasing number of studies indicate that degrees of hepatotoxicity have been associated with using some of these medications in the management of COVID-19 patients. Significantly, it was relieved after the cessation of these agents. However, to our knowledge, no studies have systematically investigated the evidence of DILI in COVID-19 patients. In this review, we discussed the association between hepatotoxicity in COVID-19 patients and the drugs used in these patients and possible mechanisms of hepatotoxicity. The currently available evidence on the association of different therapeutic agents with hepatotoxicity in COVID-19 patient was systematically reviewed.

    Key Words: Liver injury; COVID-19; Anti-COVID drugs; Mechanisms; Clinical evidences

    INTRODUCTION

    A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially discovered in Wuhan, China in early December 2019. This discovery was followed by an outbreak that spread across the globe. SARS-CoV-2 is a new pathogen in the coronavirus family, and the condition it causes is called coronavirus disease 2019 (COVID-19), a severe acute respiratory condition[1]. As of August 28, 2022, over 598 million confirmed cases and over 6.4 million deaths had been reported globally by the World Health Organization[1]. Patients commonly present with symptoms of fever, dry cough, and fatigue; however, symptom severity varies. Severe symptoms include respiratory distress, high-grade fever, chest discomfort, and loss of appetite. The disease is usually self-limiting,with recovery in nearly 80% of patients with no significant interventions required. Up to 15% may need respiratory support, and 5% of patients need intensive care due to severe disease[2,3].

    COVID-19 consists of a systemic disease that can present numerous complications. Complications from the severe illness include acute respiratory distress syndrome, septic shock, and thrombolytic and multiorgan failure affecting the liver, heart, and kidneys[4]. The virus can affect not only the lungs of the patient but also other tissues that express the angiotensin-converting enzyme (ACE)-2 receptor, such as the vascular endothelium, gastrointestinal tract, and squamous epithelium of the nasal, oral mucous,and pharynx. Therefore, COVID-19 is a systemic illness that may cause arrhythmia, thrombolytic episodes, prolongation of the QT interval, acute coronary syndrome, myocardial dysfunction,ketoacidosis, hepatocellular damage, kidney injury, neurological symptoms, hyperglycemia, sepsis, and,in more severe cases, multiorgan failure.

    Patients with COVID-19 experience various degrees of liver function abnormalities. Numerous studies have demonstrated that liver damage is frequent in people with COVID-19 and may contribute to the severity of the disease[5-7]. Liver damage can be complicated and varied, requiring a thorough investigation and continuous monitoring. In the context of COVID-19, clinicians will have to determine whether the liver injury is related to underlying liver disease, drugs used to treat COVID-19, the direct effect of the virus, or a complicated disease course. Recent studies have suggested a number of potential mechanisms of probable liver injury in COVID-19 patients. However, the exact cause and specific means of COVID-associated liver injury need to be elucidated further. Drug-induced liver injury (DILI) should be closely monitored in COVID-19 patients, especially considering the widespread off-label usage of medications in preventive and therapeutic regimens.

    Liver disorders in COVID-19 patients using several concomitant off-label drugs (potentially causing further liver damage) should be a warning sign for rapid identification and early intervention, thus preventing severe impairment in patients. The inherent liver damage associated with COVID-19 patients and the use of numerous concurrent off-label medications leading to increased severity of liver damage should be a warning indicator for early diagnosis and treatment, averting severe impairment in COVID-19 patients. This review summarizes current evidence related to hepatobiliary complications in COVID-19, provides an overview of the available evidence and critically elucidates the proposed mechanisms. We anticipate that this review will assist medical professionals in developing more effective methods for managing such patients.

    COVID-19 AND ITS IMPACT ON THE LIVER

    The effect of COVID-19 on liver functions can be observed by abnormalities in the levels of liver enzymes. There may be a decrease in the albumin levels as well as increasing bilirubin levels.Laboratory findings of liver injury include an increase in aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase, lactate dehydrogenase,hyperbilirubinemia, prolonged prothrombin time. and hypoalbuminemia (Table 1)[8-11].

    Any alterations in liver function can be either due to parenchymal injury, cholestasis, or mixed type of etiology[12,13]. The incidence of a parenchymal, cholestatic, and mixed form of liver injury was observed to be 75.0%, 29.2%, and 43.4%, respectively, in patients with COVID-19 infections. The elevation in liver enzymes (AST and ALT) was found to be within five times the upper limit of normal.The rates of ALT and AST increases were observed to be in a range of 2.5%-50.0% and 2.6%-61.1%,respectively. It was observed that 56% elevation in AST and 28% in ALT was observed in those patients who had severe COVID-19 infection[14]. Elevation of gamma-glutamyl transferase may occur in up to 28% of patients, whereas ALT elevation was observed in nearly 23% of patients as are the AST levels.Increases in gamma-glutamyl transferase have been observed to increase mostly in severe forms of infection and could be possibly linked to drug toxicity[15]. AST level increases can be linked to hepatocyte injuries and mitochondrial damage by the virus. It was observed that an AST/ALT ratio > 1 helps predict the occurrence of severe pneumonia, need for intensive care, and risk of mortality.Elevations in ALP were rare but occurred in patients who had either multiorgan failure, liver failure or died due to COVID-19 infection[16].

    Liver damage in patients with COVID-19 is currently limited to moderate to severe cases and the damage may be transient, with liver tests returning to normal without needing specific treatment[4,17].The acute or chronic liver failure occurrence is yet to be investigated. However, the severity of the condition, the likelihood that a patient would require admission to the intensive care unit or a lengthy hospital stay[18], and the risk of death, all increase with higher serum levels of AST/ALT and total bilirubin[19]. In patients with pre-existing conditions, the occurrence of liver injury may be aggravated or accelerated. Some of these conditions include fatty liver disease with co-existing metabolic disorders,reactivation of viral hepatitis, as well as other causes of chronic liver diseases.

    Some liver biopsy and histopathology specimens that were analyzed from patients with COVID-19 showed moderate microvascular steatosis and mild lobular and portal vein activity. There was evidence of infiltration of lymphocytes, sinusoidal expansion of the central lobule, and patchy necrosis[4]. There were no signs of severe liver injury such as extracellular fibrosis, coagulation necrosis, or severe cholestasis in the biopsy specimens examined. The difficulty to perform autopsy and liver biopsies of COVID-19 patients due to the virus’ high transmissibility and the lack of guidelines for defending medical practitioners during the start of the pandemic lead to the deficit of histological information in the literature[17].

    Several studies have reported that severe cases of COVID-19 were more likely to have severe liver injury than mild cases[20-22]. Male patients were more likely to have liver function injuries than females(P< 0.05)[23]. The association of multiorgan abnormalities has also been observed to correlate with the severity of the disease and the worsening of clinical outcomes. Liver involvement is not necessarily associated with a picture of multiorgan failure but may be seen in early disease stages. However, in these patients, there is no need for additional therapy for recovery of hepatic functions and is generally reversible. The frequency of liver damage in COVID-19 patients ranges from 14.8% to 53.0%[24].

    POTENTIAL MECHANISMS OF LIVER INJURY IN PATIENTS WITH COVID-19

    Direct effect of viral infection on the liver

    The etiopathogenesis of liver damage related to direct COVID-19 infections has not been completely determined yet. However, it is hypothesized to be direct hepatocellular damage, as is observed by the elevation in the cytonecrosis enzymes levels (Figure 1). ACE2 is a key receptor of the SARS-CoV-2 virus[25]. The ACE2 receptor is expressed in the lungs and the bile duct cells and acts as a gateway for the entry of the virus. The cell-specific expression of the ACE2 receptor in healthy liver tissues was evaluated by Chaiet al[6] and found that ACE2 was expressed in 2.6% of hepatocytes and 59.7% of cholangiocytes, suggesting that liver injury may be caused by direct viral invasion. The hypothesis of direct viral damage can also be explained by liver biopsies that show signs of hepatocyte apoptosis,along with the presence of viral RNA in the tissue[26]. A recent study by Wuet al[27] found that half of the COVID-19-infected patients who had completely cleared respiratory tract infections had virus shedding in their fecal specimens up to 11 d after viral detection in the respiratory tract samples became negative. This suggests that there may be viral replication in extrapulmonary sites (digestive tract and liver).

    Role of endotheliitis in hepatic injury

    Another suggested mechanism of liver injury is secondary to the hypercoagulability leading to thrombosis of the portahepatic system. Occurrence of hypoxia as a result of pulmonary involvement may lead to a state of hypoxia in liver tissue followed by reperfusions, thereby causing an influx of reactive oxygen species and worsening the proinflammatory state[28]. The inflammation of the vascular endothelium caused by SARS-CoV-2 infection leads to microvascular dysfunction, which leads to a hypercoagulable state, tissue edema, and organ ischemia[29,30]. It was previously reported that a variety of viruses, such as dengue fever virus, human immunodeficiency virus (HIV), and Ebola virus,have been affecting the coagulation system[29]. The underlying mechanism of the hepatic injury associated with COVID-19 may be the liver ischemia-reperfusion injury, a pathophysiological process that frequently occurs following a rapid recovery of blood circulation to the liver tissue. When there is vascular endothelial damage, either directly by virus or through immune-mediated inflammation, the vessels have a vasoconstriction and procoagulant state (Figure 1). Studies in the literature demonstrated significantly higher plasma levels of fibrinogen and D-dimer in severe cases of COVID-19 than those in healthy controls[31-33].

    Table 1 Clinical evidence of coronavirus disease 2019-mediated impact on various biochemical indexes

    Inflammatory storm in COVID-19-associated hepatic injury

    The excessive immune response induced by COVID-19 infection causes an inflammatory cytokine storm that might also be one of the critical factors in hepatic injury (Figure 1)[34,35]. Lower lymphocyte counts(both helper T cells and suppressor T cells) and higher plasma levels of various inflammatory cytokines[monocyte chemoattractant protein 1, interleukin (IL)-2, IL-10, IL-7, GCSF, MIP1A, IP10, and tumor necrosis factor-alpha] were commonly observed in patients with COVID-19, especially in the critically ill patients[3,36]. Increases in IL-6 and IL-10 as well as a decrease in CD4+ T cells were found to be independent risk factors for severe liver damage in a cohort study of 192 patients[37]. Another study discovered an independent relationship between lymphopenia and C-reactive protein levels and hepatic damage[38].

    Systemic inflammatory response syndrome in patients presenting with moderate to severe illness leads to uncontrolled immune-mediated inflammatory response secondary to the release of cytokines and other inflammatory markers such as interleukins and tumor necrosis factors. The state of cytokine storm leads to secondary liver injury by causing systemic inflammation, and the patients can often present with multiorgan failure[39].

    The liver injury associated with COVID-19 was determined to lead to a poorer patient outcome. This could be due to the involvement of other organ systems as well. In severe and critical patients, there was a rise in the biomarkers of inflammation, myocardial injury, liver and kidney functions, and coagulation functions[20]. Patients with liver injury usually had a longer hospital stay, and in those with a preexisting liver disease, the risk of hospitalization and mortality was higher. Systematic reviews have shown that an elevation in liver biochemistry during the first visit was also found to be an indicator of the disease severity.

    In a metanalysis of over 15000 patients with COVID-19, liver injury was reported in 23.1% patients in the early period and 24.4% incidence in the overall disease course. They found that 48.5% of the cases of liver injury were reported within the 1st2 wk of admission, and 26.7% patients with severe pneumonia had liver injury as well[12]. The incidence of liver injury in patients who have died from COVID-19 was found to be as high as 58%-78%[40,41].

    The poor prognosis of patients developing liver injury is possibly related to patients older than 60 years, severe COVID-19 infection, and underlying metabolic diseases such as hypertension and diabetes. Therefore, it was concluded that for patients with other comorbidities, there is a greater need for in-depth monitoring and individualizing the treatment given[42].

    COVID-19 DILI: An overview

    Figure 1 Molecular mechanisms of severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 drug-induced liver injury. 1: Direct action of the virus, i.e., angiotensin-converting enzyme 2 receptor mediated action; 2: Immuno-inflammation caused by cytokine storm leading to liver damage; 3: Hepatocellular apoptosis induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; 4: SARS-CoV-2-induced thrombosis leading to vascular endothelial damage and causing hypoxic-ischemic liver injury; 5: Several drugs and therapies used to counteract coronavirus disease 2019 including antivirals, immunomodulatory agents, and vaccines reportedly led to abnormal liver enzymes causing drug-induced liver injury. All these mechanisms aggravate liver injury by causing abnormal liver enzymes like increasing the levels of alanine aminotransferase, aspartate transaminase, alkaline phosphate, gammaglutamyl transferase, lactate dehydrogenase, and total bilirubin and reducing the albumin levels. ACE2: Angiotensin converting enzyme-2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

    DILI is a rare diagnosis and can occurviamany drugs, leading to liver damage. DILI may be severe but rarely fatal; recovery after drug discontinuation generally occurs. DILI is defined by increased liver enzymes either due to hepatocellular necrosis, cholestasis, or both[43]. The hepatocellular injury pattern resembles acute viral hepatitis-induced injury, hallmarked by hepatocyte necrosis and inflammation.Agents that typically cause this injury pattern include isoniazid, nitrofurantoin, and methyldopa.Cholestatic injury resembles bile duct obstruction, hallmarked by bile stasis, portal inflammation, and proliferation or injury of bile ducts and ductules. Drugs that exhibit this type of injury include amoxicillin/clavulanate, ciprofloxacin, and sulfonylureas. Mixed type liver injury is most characteristic of DILI, with the liver biopsy showing necrosis and inflammation along with bile stasis[44].

    DILI may be caused by either an intrinsic or a distinctive mechanism. The clinical pattern associated with DILI is usually varied and can mimic other forms of liver disease. The patient’s presentation can resemble acute hepatitis, acute liver failure, chronic hepatitis, biliary obstruction, or fatty liver disease.As the evidence of DILI concerning various drugs is often large and scattered across multiple disciplines, it becomes difficult for clinicians and researchers to search for evidence related to each drug.Therefore, the reference for the most established evidence related to a drug and its ability to cause liver injury isviadatabases such as LiverTox[44].

    Intrinsic DILI is usually dose-dependent and predictable and occurs after a brief latency period. The most common DILI is idiosyncratic, and it is primarily unpredictable, with a variable latency period[45]. The severity of DILI may vary, and up to 10% of severe cases may need a liver transplant for the same. Mortality is three times higher in patients with pre-existing liver disease, along with a DILI.Monitoring is vital in a patient exhibiting signs of DILI. Any signs of jaundice, hyperbilirubinemia,hepatomegaly, or new onset right upper quadrant pain warrant further investigations and discontinuation of the suspected drugs[4]. Mostly, liver injury is reversible, with recovery after drug discontinuation. One possible treatment option is ursodeoxycholic acid, which protects elevated transaminase and serum total bilirubin levels[46].

    The Roussel Uclaf Causality Assessment Method scale is a seven-domain scale, which considers the temporal association of liver injury, various risk factors such as age, alcohol intake, and concomitant hepatotoxic drugs, and occurrence of repeated liver damage on the administration of the suspect drug.It also helps in the exclusion of other causes of transaminase elevations, such as ischemia, myositis,cytokine storm, and previous chronic liver disease[4].

    The societal pressures of COVID-19 infections, including hospital bed shortages and added stress to the health system, are further compounded by liver injury secondary to drug use. Although in mild to moderate cases, the risk of mortality remains low, it still leads to the added burden on healthcare systems due to prolongation of hospital stays and an increased risk of contracting a nosocomial infection[47].

    The treatment of COVID-19 saw the use of many therapeutic options, from the repurposing of older drugs to new drug trials and the administration of new vaccines to prevent infection. Assessing the hepatotoxicity profile of drugs used in COVID-19 is complicated as many drugs have been used offlabel and with dosages not routinely used. Thereby, reports of DILI may be rarely encountered in routine practice with some drugs but may be more often when used in COVID-19[48].

    LITERATURE REVIEW

    The general information on SARS-CoV-2-associated hepatic injury was gathered by using a systematic search strategy. The eligible systematic reviews, meta-analysis, and review articles on COVID-19-induced and COVID-19 DILI were searched in four databases: EMBASE, Scopus, MEDLINE, and Web of Science. The literature search was performed through September 5, 2022 and terms used for search across all the databases included: ((COVID-19) AND (Drug-induced) AND (Hepatotoxicity)) OR((SARS-CoV-2) AND (Drug-induced) AND (Hepatotoxicity)) OR ((COVID-19) AND (Drug-induced)AND (Hepatic injury)) OR ((SARS-CoV-2) AND (Drug-induced) AND (Hepatic injury)) OR ((COVID-19) AND (Drug-induced) AND (Liver injury)) OR ((SARS-CoV-2) AND (Drug-induced) AND (Liver injury)). The search returned a total of 113 articles, which were further screened for duplicates. A total of 56 articles were included, all fitting the eligible criteria,i.e.,reviews and meta-analyses on COVID-19-induced and COVID-19 DILI.

    Evidence of hepatotoxicity risk associated with COVID-19 therapy

    One meta-analysis reported the incidence of drug toxicity with COVID-19 therapy as high as 25.4%[49].Some of the most commonly reported cases of hepatotoxicity have been associated with the prescription of antipyretics such as acetaminophen, anti-inflammatories such as tocilizumab, and antivirals such as favipravir, remdesivir, lopinavir/ritonavir (LPV/r), chloroquine, oseltamivir, and ribavirin (Table 2). In patients with pre-existing chronic liver disease or with severe infection, the risk of developing hepatotoxicity was reported to be higher[50]. The liver is the leading site for metabolism and elimination for many drugs. Some of the drugs that were repurposed for COVID-19 treatments such as nucleoside analogs and protease inhibitors are primarily metabolized in the liver[10] (Table 2).

    ANTIVIRAL DRUGS AND LIVER INJURY

    One of the antiviral drugs explored for therapy in COVID-19 included lopinavir-ritonavir, a combination widely prescribed in the treatment of HIV/AIDS. As a combination, it has been previously reported to be associated with moderate to severe elevations in serum aminotransferases. The mechanism of liver injury is probably due to metabolism through the CYP3A4 system[51]. Various studies reported liver function abnormalities when patients were treated with LPV/r[52]. The incidence of reported adverse events with the use of this combination was as high as 63.8% in one study, with the second most common adverse event being liver injury[53] (Table 2).

    A pooled meta-analysis reported the incidence of DILI with LPV/r as 37.2%[49]. Once hepatotoxicity develops with LPV/r or ribavirin, restarting the drug is not recommended[54]. LPV/r prescription is associated with moderate to severe elevations in serum transaminase levels. Ritonavir, given as a boosting drug in this combination, acts as an enzyme inhibitor and may also lead to compounded hepatotoxicity of co-administered medicines[55] (Table 2).

    Favipiravir is an inhibitor of RNA-dependent RNA polymerase enzyme. It has shown efficacy against Ebola, West Nile virus, yellow fever virus, and influenza. It acts by embedding in the viral RNA,causing mutations and leading to viral death[56]. It has been demonstrated to have activity against the SARS-CoV-2 virus by interfering with the viral replication by competing with the purine nucleosides.There have been some reports of elevation in the hepatic transaminases with favipiravir therapy, but it was generally mild and reversible[57] (Table 2).

    Table 2 Clinical evidence of coronavirus disease 2019 drug-induced liver injury

    Enoxaparin It is low molecular weight heparin and was indicated in thromboembolic venous complications of COVID-19 Elevated serum AST levels and mild elevation in serum alkaline phosphate and total bilirubin levels[10,11,13,52]LMWH It is an anticoagulant used in COVID-19 to reduce the risk of thromboembolism LMWH are associated with acute hepatotoxicity, and elevations in the liver enzymes are usually observed after 5-8 d of initiation of therapy[74,85]SARS-CoV-2 vaccines (Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca)mRNA and viral vector encoding SARS-CoV-2 spike protein were used for vaccinations in healthy subjects The clinical phenotype is mostly hepatocellular and showed features of immune-mediated hepatitis[77,78]ALT: Alanine aminotransferase; AST: Aspartate transaminase; ACE: Angiotensin converting enzyme; IL-6: Interleukin 6; LMWH: Low molecular weight heparin; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

    Oseltamivir has also been initially explored for therapy in patients with COVID-19. The efficacy of oseltamivir could not be established in various trials and is now no longer prescribed. Some case reports have reported a transient rise in liver enzymes associated with its use; however evidence in COVID-19 is lacking[58]. Umifenovir is used for influenza treatment and was prescribed initially in COVID-19 in China. It is metabolizedviaCYP3A4, and this mechanism may be associated with the occurrence of DILI. Its use in cirrhotic patients is cautioned due to risk of liver injury[59,60] (Table 2).

    Remdesivir is a nucleotide analogue that was explored for the treatment of hepatitis C virus and Ebola. One case series reported 25% and 33% increases AST and ALT, respectively[61]. The risk of abnormalities in the AST and ALT levels were higher with the use of remdesivir as compared to any other therapy for COVID-19. Elevations were noted immediately after starting remdesivir, but the gradual improvement was noted afterwards[62]. Prior to starting remdesivir, a baseline liver function test should be obtained. If the transaminase level is increased more than 10 times, then the use of remdesivir should be discontinued[63]. However, hepatotoxicity is generally asymptomatic, fully reversible, and not associated with any jaundice[64] (Table 2).

    IMMUNOMODULATORS AND LIVER INJURY

    Hydroxychloroquine and chloroquine are immunomodulator drugs, mainly used in autoimmune disorders. During the early days of the pandemic, these drugs were widely explored for the treatment of COVID-19 infections due to their proposed role in decreasing the hyperinflammatory states associated with COVID-19. Hydroxychloroquine is metabolized in the liver, and its metabolites may also accumulate in the liver leading to hepatotoxicity, although rarely reported[44]. One case of a 10-fold increase in transaminases was reported with administration of hydroxychloroquine, which was reversible and recovery occurred after withdrawal of the drug[65] (Table 2).

    Tocilizumab is a monoclonal antibody against the IL-6 receptor and is indicated for use in cytokine storm associated with severe disease. It has received Food and Drug Administration approval for use in COVID-19 infections. It has been demonstrated to have a transient elevation in the hepatic enzymes, but rare cases of severe liver injury have occurred[55]. Patients with a pre-existing hepatitis B viral infection have experienced reactivation of the virus after treatment with tocilizumab[66]. The recommendation suggests patients treated with tocilizumab should receive regular liver function test monitoring, and hepatitis B virus-DNA levels should be rechecked in patients with pre-existing infections after discharge from the hospital[39] (Table 2).

    Baricitinib, tofacitinib, and imatinib belong to a class of Janus kinase inhibitors. Of these, baricitinib has been used the most for treating COVID-19 because of its effect on decreasing the inflammatory response to COVID-19 infection[67]. There is evidence of a nearly 1% incidence of liver enzyme and bilirubin increases with patients, but no data has been published so far for patients with COVID-19. In the randomized controlled trial conducted for baricitinib in COVID-19, there were no reports of liver damage[68] (Table 2).

    Azithromycin was widely used in the beginning of the pandemic, as it had some demonstrated antiviral and anti-inflammatory activity[69]. Combined use of hydroxychloroquine and azithromycin was explored by a French study. However, the findings were disputed, and the study was withdrawn[70]. Azithromycin has a concern over causing cardiotoxicity, but there have been instances of hepatotoxicity reported with azithromycin use as well[44]. The risk of liver injury is higher in patients with pre-existing liver disease, and they are at a higher risk of developing more severe complications[71](Table 2).

    MISCELLANEOUS THERAPIES AND LIVER INJURY

    Paracetamol has both antipyretic and analgesic effects and is a well-known cause of dose-dependent DILI; it is usually difficult to manage and can be fatal to the patients. The underlying mechanism for toxicity is direct damage through a metabolite generated from liver metabolism[72]. Paracetamol is used as an adjunct therapy, along with many other medications, but the actual incidence of hepatotoxicity associated with acetaminophen is still undetermined[73] (Table 2).

    Low molecular weight heparin is one of the most commonly prescribed anticoagulants used in COVID-19 to reduce the risk of thromboembolism and its sequelae. Low molecular weight heparin is known to cause hepatotoxicity in the range of 4.3%-13.0%[74]. Liver enzyme elevation usually occurs 5-8 d after initiation of therapy and are reported to normalize within 2 wk of stopping the drugs[75](Table 2).

    One of the cornerstones of treatments is the systemic administration of corticosteroids. Corticosteroids have been shown to reduce mortality in mechanically ventilated patients and in patients who require supplemental oxygen support at the time of admission. Although, corticosteroid use is associated with many adverse events, ranging from deranged glycemic control to thromboembolism,secondary infections and reactivation of hepatitis B infection[39]. The prolonged use of corticosteroids may be associated with hepatic steatosis. However, this effect is less likely to be seen with the relatively short duration of corticosteroid therapy in COVID-19 infections[76] (Table 2).

    Vaccinations in healthy subjects for prophylaxis against COVID-19 had been reported to be associated with acute liver injury in some patients. A world-wide case series involving 87 patients administered with COVID-19 vaccines, including 59% of cases with the Pfizer-BioNTech (BNT162b2) vaccine, 23% of cases with the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine, and 18% of cases with the Moderna(mRNA-1273) vaccine, had reported clinical features of acute liver injury associated with SARS-CoV-2 vaccination[77,78]. However, the benefits of COVID-19 vaccines during the pandemic cannot be neglected because of the rare events of liver injury in the small proportion of the overall vaccinated population (Table 2).

    DIAGNOSIS AND MANAGEMENT OF DILI

    DILI is a diagnosis by exclusion. Patient workup includes thorough patient history, including a history of chronic liver disease, alcohol or drug abuse, and complete information on past and concomitant drug history[79]. A complete history of herbal and dietary supplement use should also be taken[80]. Patients developing liver injury require regular monitoring of ALT, AST, total and direct bilirubin, albumin,prothrombin time, and international normalized ratio[24].

    According to the updated Roussel Uclaf Causality Assessment Method, the cutoffs for the diagnosis of DILI is as follows: ALT > 5 times the upper limit of normal and/or ALP > 2 times upper limit of normal. Based on the ratio of serum ALT to ALP values (R-value), DILI pattern may be hepatocellular (≥5), cholestatic (≤ 2), or mixed (> 2 and < 5)[43]; 50% of the patients with DILI exhibit a hepatocellular pattern[64].

    Acute liver injury in patients with COVID-19 is usually mild and is transient, with recovery without requiring any specific therapy[79]. However, supportive therapy is often needed, such as albumin infusion or administration of fresh frozen plasma. In patients with pre-existing liver dysfunction and severe infection, the drugs prescribed should be carefully monitored, taking care that no more than two drugs with the potential to cause DILI should be administered at the same time. Also, regular monitoring of liver functions should be done for such patients. If patients develop DILI, early discontinuation should be initiated, or dosage should be altered if complete discontinuation is not possible[81].

    There are no defined guidelines for managing DILI in patients with COVID-19. The most effective option available is to discontinue the offending agent. This leads to recovery in 90% of patients. In cases where required, therapy can be initiated with medications such as ursodeoxycholic acid[82]. Some other therapeutic options available include drugs such as polyene phosphatidylcholine, glycyrrhizic acid, and adenosylmethionine. Glycyrrhizic acid has been demonstrated to have a strong affinity for liver enzymes and has anti-inflammatory, anti-allergic, and hepatoprotective effects[52]. Patients with COVID-19 are at a higher risk of hepatic injury, and therefore drugs such as nonsteroidal anti-inflammatory drugs, acetaminophen, and antibiotics, which have the potential of causing liver injury, should be given to these patients cautiously. A small number of healthy subjects presented SARS-CoV-2 vaccination-associated liver injury, predominantly immune-mediated hepatitis, were managed using corticosteroid therapy[78].

    CONCLUSION

    There are variable degrees of impaired liver function in patients with COVID-19. Liver damage can be complicated and varied, requiring significant investigations and continuous monitoring. Clinicians treating patients with COVID-19 must first evaluate if the liver damage is a result of underlying liver illness, therapies used to treat COVID-19, a direct result of the virus, or a complex disease course. Recent studies proposed a number of mechanisms regarding possible causes of liver damage in COVID-19 patients. This review gave an overview of the case series that are currently available, highlighted the most recent research on hepatobiliary consequences in COVID-19, and critically explained the putative mechanisms underlying liver damage. We anticipate that this review will assist medical professionals in creating more effective plans for managing such patients.

    FOOTNOTES

    Author contributions:All authors were equally involved in the literature search and manuscript writing and editing.

    Conflict-of-interest statement:All authors report having no relevant conflicts of interest for this article.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:India

    ORCID number:Lekha Saha 0000-0001-5925-7159.

    S-Editor:Wang JJ

    L-Editor:Filipodia

    P-Editor:Wang JJ

    国产精品免费一区二区三区在线| 国产精品一区二区在线不卡| 看片在线看免费视频| 曰老女人黄片| 国产又爽黄色视频| 国产成人精品久久二区二区91| 国产欧美日韩一区二区精品| 成人18禁高潮啪啪吃奶动态图| 亚洲一区中文字幕在线| av在线播放免费不卡| 露出奶头的视频| 欧美乱妇无乱码| 欧美国产日韩亚洲一区| 少妇 在线观看| 国产一区在线观看成人免费| 国产成人精品久久二区二区91| 首页视频小说图片口味搜索| 中文字幕精品免费在线观看视频| 亚洲国产毛片av蜜桃av| 欧美日韩中文字幕国产精品一区二区三区 | 国产精品爽爽va在线观看网站 | 国产麻豆69| 一级毛片女人18水好多| 亚洲成人久久性| 91麻豆精品激情在线观看国产| 69av精品久久久久久| 亚洲成a人片在线一区二区| 免费一级毛片在线播放高清视频 | 国内精品久久久久久久电影| 国产伦一二天堂av在线观看| 韩国精品一区二区三区| 国产av精品麻豆| 国产成人一区二区三区免费视频网站| 9191精品国产免费久久| 午夜福利18| 国产成人精品在线电影| 欧美丝袜亚洲另类 | 日日干狠狠操夜夜爽| 亚洲免费av在线视频| 精品卡一卡二卡四卡免费| 999久久久国产精品视频| 91精品三级在线观看| 免费看十八禁软件| 91老司机精品| 日本免费一区二区三区高清不卡 | 亚洲一区二区三区不卡视频| 亚洲少妇的诱惑av| av有码第一页| 很黄的视频免费| 看黄色毛片网站| 麻豆久久精品国产亚洲av| 91字幕亚洲| 亚洲专区中文字幕在线| 日韩成人在线观看一区二区三区| 99久久久亚洲精品蜜臀av| 国产午夜福利久久久久久| 99久久久亚洲精品蜜臀av| 国产三级在线视频| 人人妻人人澡欧美一区二区 | 最新在线观看一区二区三区| 校园春色视频在线观看| 亚洲国产精品久久男人天堂| 可以在线观看毛片的网站| 女人爽到高潮嗷嗷叫在线视频| 欧美 亚洲 国产 日韩一| 亚洲av五月六月丁香网| 男女做爰动态图高潮gif福利片 | 免费无遮挡裸体视频| 99re在线观看精品视频| 午夜福利在线观看吧| 欧美国产日韩亚洲一区| 国产午夜福利久久久久久| 国产精品一区二区三区四区久久 | 久久这里只有精品19| 久久 成人 亚洲| ponron亚洲| 久久久久久国产a免费观看| 可以在线观看的亚洲视频| 成人欧美大片| 最好的美女福利视频网| 51午夜福利影视在线观看| 精品日产1卡2卡| 在线十欧美十亚洲十日本专区| 中文字幕人成人乱码亚洲影| 日韩大码丰满熟妇| 欧美国产日韩亚洲一区| 12—13女人毛片做爰片一| 亚洲精品美女久久av网站| 真人一进一出gif抽搐免费| 国内精品久久久久精免费| 12—13女人毛片做爰片一| 亚洲中文av在线| 国产成人一区二区三区免费视频网站| 又黄又爽又免费观看的视频| 国产欧美日韩一区二区三| 午夜免费激情av| 午夜免费鲁丝| 亚洲 国产 在线| 亚洲狠狠婷婷综合久久图片| 午夜福利成人在线免费观看| 久久久久国产精品人妻aⅴ院| 99久久久亚洲精品蜜臀av| АⅤ资源中文在线天堂| 女人被狂操c到高潮| 在线国产一区二区在线| 午夜精品在线福利| 日本在线视频免费播放| 老熟妇乱子伦视频在线观看| 在线永久观看黄色视频| 国产欧美日韩综合在线一区二区| 国产精品乱码一区二三区的特点 | 亚洲在线自拍视频| 婷婷精品国产亚洲av在线| 日韩视频一区二区在线观看| 成熟少妇高潮喷水视频| 美女国产高潮福利片在线看| 88av欧美| 最新在线观看一区二区三区| 国产亚洲av高清不卡| 天堂动漫精品| 国产亚洲欧美98| 天天一区二区日本电影三级 | 亚洲精品av麻豆狂野| 亚洲av成人不卡在线观看播放网| 人成视频在线观看免费观看| 淫妇啪啪啪对白视频| 色哟哟哟哟哟哟| 亚洲中文av在线| 久久久久久亚洲精品国产蜜桃av| 色婷婷久久久亚洲欧美| 日韩欧美一区视频在线观看| 欧美成狂野欧美在线观看| 看免费av毛片| 欧美av亚洲av综合av国产av| 日韩大码丰满熟妇| 国产亚洲精品av在线| 日韩成人在线观看一区二区三区| 视频在线观看一区二区三区| 国内精品久久久久精免费| 韩国精品一区二区三区| 高清黄色对白视频在线免费看| 午夜成年电影在线免费观看| 天天躁夜夜躁狠狠躁躁| 大型av网站在线播放| 日本在线视频免费播放| 亚洲av成人不卡在线观看播放网| 亚洲精品中文字幕一二三四区| 成人18禁在线播放| 大型黄色视频在线免费观看| 久久亚洲真实| 中文字幕高清在线视频| 国产主播在线观看一区二区| 亚洲一卡2卡3卡4卡5卡精品中文| 国产精品国产高清国产av| 精品国产美女av久久久久小说| 如日韩欧美国产精品一区二区三区| 国产精品电影一区二区三区| avwww免费| 午夜精品在线福利| 女性被躁到高潮视频| 国产一卡二卡三卡精品| 十分钟在线观看高清视频www| 曰老女人黄片| 久久久久久大精品| 国内久久婷婷六月综合欲色啪| 一区二区三区激情视频| 91av网站免费观看| 亚洲欧洲精品一区二区精品久久久| 身体一侧抽搐| av在线天堂中文字幕| tocl精华| 精品一区二区三区av网在线观看| 国产视频一区二区在线看| 免费少妇av软件| 美女高潮到喷水免费观看| www.www免费av| 最新在线观看一区二区三区| 国产伦一二天堂av在线观看| 波多野结衣高清无吗| 黄片小视频在线播放| av视频在线观看入口| 日韩有码中文字幕| 国产激情欧美一区二区| 免费在线观看视频国产中文字幕亚洲| 国产精品亚洲美女久久久| 免费观看精品视频网站| 成年女人毛片免费观看观看9| 制服诱惑二区| 亚洲国产欧美一区二区综合| 两个人视频免费观看高清| 免费看美女性在线毛片视频| 19禁男女啪啪无遮挡网站| 国产成年人精品一区二区| 婷婷六月久久综合丁香| 两个人免费观看高清视频| 在线观看免费视频网站a站| 亚洲自拍偷在线| 男女做爰动态图高潮gif福利片 | 日韩欧美在线二视频| 久久国产精品影院| 欧美激情高清一区二区三区| 久久青草综合色| 亚洲国产精品sss在线观看| 高清毛片免费观看视频网站| 免费在线观看视频国产中文字幕亚洲| 黄色视频不卡| 成人18禁在线播放| 黑人巨大精品欧美一区二区蜜桃| 亚洲五月婷婷丁香| 美国免费a级毛片| 一进一出好大好爽视频| 精品久久蜜臀av无| 国产成人欧美| 久久久久久久久久久久大奶| 色播在线永久视频| 欧美黑人欧美精品刺激| 欧洲精品卡2卡3卡4卡5卡区| 亚洲少妇的诱惑av| 男人操女人黄网站| 亚洲精品一卡2卡三卡4卡5卡| 国产精品九九99| 欧美日韩亚洲国产一区二区在线观看| 久久久久亚洲av毛片大全| 亚洲精华国产精华精| 精品高清国产在线一区| 男女床上黄色一级片免费看| 午夜福利成人在线免费观看| 国产精品影院久久| 亚洲人成电影观看| 成人国产综合亚洲| 久久中文字幕人妻熟女| 亚洲在线自拍视频| 黄色女人牲交| 大码成人一级视频| 亚洲 国产 在线| 一级片免费观看大全| 国产精品野战在线观看| 亚洲,欧美精品.| 97超级碰碰碰精品色视频在线观看| 女同久久另类99精品国产91| 狠狠狠狠99中文字幕| 怎么达到女性高潮| 国产免费av片在线观看野外av| 国产麻豆69| 国产精品亚洲一级av第二区| 满18在线观看网站| 丁香六月欧美| 天堂动漫精品| 久久久久精品国产欧美久久久| 日本五十路高清| 国产精华一区二区三区| www日本在线高清视频| 国产欧美日韩精品亚洲av| 婷婷丁香在线五月| 波多野结衣高清无吗| a在线观看视频网站| 国产成+人综合+亚洲专区| 亚洲成av片中文字幕在线观看| 欧美成人免费av一区二区三区| ponron亚洲| 18美女黄网站色大片免费观看| 亚洲国产日韩欧美精品在线观看 | 在线观看午夜福利视频| 欧美精品啪啪一区二区三区| 露出奶头的视频| 国产aⅴ精品一区二区三区波| 女人高潮潮喷娇喘18禁视频| 久久久国产成人免费| 欧美日韩精品网址| 欧美激情高清一区二区三区| www.熟女人妻精品国产| 亚洲国产毛片av蜜桃av| aaaaa片日本免费| 国产视频一区二区在线看| 少妇裸体淫交视频免费看高清 | tocl精华| 黄网站色视频无遮挡免费观看| 国产精品日韩av在线免费观看 | 老熟妇仑乱视频hdxx| 国产午夜精品久久久久久| 久99久视频精品免费| 看片在线看免费视频| 亚洲av成人不卡在线观看播放网| 成人亚洲精品一区在线观看| 最近最新免费中文字幕在线| 人人妻人人澡人人看| 成人亚洲精品av一区二区| 欧美一级a爱片免费观看看 | 欧美国产精品va在线观看不卡| 女性被躁到高潮视频| 夜夜看夜夜爽夜夜摸| 久久人人97超碰香蕉20202| 巨乳人妻的诱惑在线观看| 国产精品免费一区二区三区在线| 90打野战视频偷拍视频| 午夜福利在线观看吧| 国产麻豆69| 可以在线观看毛片的网站| 最好的美女福利视频网| 亚洲一码二码三码区别大吗| 黑人欧美特级aaaaaa片| 国产主播在线观看一区二区| 熟女少妇亚洲综合色aaa.| 国产三级在线视频| 免费不卡黄色视频| 亚洲伊人色综图| 久久午夜亚洲精品久久| 久久久久久免费高清国产稀缺| 亚洲aⅴ乱码一区二区在线播放 | 精品高清国产在线一区| 天堂动漫精品| 国内精品久久久久精免费| 久久天堂一区二区三区四区| 亚洲第一电影网av| av视频免费观看在线观看| 大码成人一级视频| 啦啦啦免费观看视频1| av片东京热男人的天堂| av中文乱码字幕在线| 在线观看免费午夜福利视频| 色哟哟哟哟哟哟| 十八禁人妻一区二区| 老司机在亚洲福利影院| 男女下面插进去视频免费观看| 中文字幕av电影在线播放| 日本欧美视频一区| 日韩高清综合在线| 婷婷丁香在线五月| 亚洲国产精品合色在线| 日本 av在线| 在线观看午夜福利视频| 成人欧美大片| 成人av一区二区三区在线看| 亚洲精品国产精品久久久不卡| 成人国语在线视频| 国产精品98久久久久久宅男小说| 欧美黄色片欧美黄色片| av福利片在线| 国产精品国产高清国产av| 国产精品久久久久久精品电影 | 日本一区二区免费在线视频| 欧美激情久久久久久爽电影 | 国产熟女xx| av有码第一页| 国产成人精品久久二区二区免费| 国产成人精品在线电影| 99国产精品99久久久久| 国产亚洲欧美在线一区二区| 国产成人精品久久二区二区免费| 亚洲狠狠婷婷综合久久图片| 亚洲av成人一区二区三| 国产精品精品国产色婷婷| 丝袜美足系列| 大陆偷拍与自拍| 9191精品国产免费久久| 免费看美女性在线毛片视频| 亚洲va日本ⅴa欧美va伊人久久| 丝袜美腿诱惑在线| 99国产精品一区二区三区| 国产亚洲精品久久久久5区| 美国免费a级毛片| 成在线人永久免费视频| 又黄又粗又硬又大视频| 99国产精品一区二区蜜桃av| av免费在线观看网站| 电影成人av| 国产精品99久久99久久久不卡| 色播亚洲综合网| 老司机在亚洲福利影院| 久久久久国内视频| 妹子高潮喷水视频| 久9热在线精品视频| 亚洲精品中文字幕在线视频| 中文字幕人妻熟女乱码| 亚洲全国av大片| 女警被强在线播放| 国产男靠女视频免费网站| 亚洲成a人片在线一区二区| 亚洲精品一区av在线观看| 操美女的视频在线观看| 亚洲国产精品sss在线观看| 精品久久蜜臀av无| 国产主播在线观看一区二区| 国产精品一区二区在线不卡| 亚洲精品美女久久久久99蜜臀| 欧美一级a爱片免费观看看 | 岛国视频午夜一区免费看| 国产精品一区二区免费欧美| 19禁男女啪啪无遮挡网站| 免费一级毛片在线播放高清视频 | 欧美不卡视频在线免费观看 | 国产亚洲精品久久久久5区| 熟妇人妻久久中文字幕3abv| 亚洲aⅴ乱码一区二区在线播放 | 色老头精品视频在线观看| cao死你这个sao货| 国产视频一区二区在线看| 一区二区三区精品91| 妹子高潮喷水视频| 女警被强在线播放| 两性夫妻黄色片| 久久香蕉精品热| 给我免费播放毛片高清在线观看| 麻豆久久精品国产亚洲av| av福利片在线| 最好的美女福利视频网| 成熟少妇高潮喷水视频| 国产一卡二卡三卡精品| 99精品在免费线老司机午夜| 天天添夜夜摸| 99国产精品一区二区三区| cao死你这个sao货| 又紧又爽又黄一区二区| 给我免费播放毛片高清在线观看| 亚洲专区中文字幕在线| 国产精品亚洲av一区麻豆| 亚洲欧美日韩无卡精品| 法律面前人人平等表现在哪些方面| 国产免费av片在线观看野外av| 国产aⅴ精品一区二区三区波| 天堂动漫精品| 国产亚洲精品综合一区在线观看 | 日韩三级视频一区二区三区| 在线观看舔阴道视频| 日本a在线网址| 国产精品99久久99久久久不卡| 丝袜人妻中文字幕| 国产精品综合久久久久久久免费 | 久久久久久免费高清国产稀缺| 69精品国产乱码久久久| 亚洲精品一区av在线观看| 亚洲第一欧美日韩一区二区三区| 亚洲精品久久成人aⅴ小说| 制服人妻中文乱码| 99在线人妻在线中文字幕| 亚洲国产欧美网| 男女之事视频高清在线观看| 国产91精品成人一区二区三区| 制服人妻中文乱码| 国产亚洲欧美在线一区二区| 搞女人的毛片| av超薄肉色丝袜交足视频| 日本黄色视频三级网站网址| 可以在线观看的亚洲视频| 国产av在哪里看| 少妇的丰满在线观看| 一区二区日韩欧美中文字幕| 国内精品久久久久精免费| 90打野战视频偷拍视频| 亚洲一区中文字幕在线| 青草久久国产| 欧美+亚洲+日韩+国产| 久久精品国产99精品国产亚洲性色 | 日韩视频一区二区在线观看| 国产精品亚洲美女久久久| 成人免费观看视频高清| 91精品国产国语对白视频| 91成年电影在线观看| 亚洲自偷自拍图片 自拍| 电影成人av| 国产一级毛片七仙女欲春2 | 久久精品国产99精品国产亚洲性色 | 女性生殖器流出的白浆| 可以在线观看毛片的网站| 免费高清视频大片| 精品高清国产在线一区| 国产成人精品久久二区二区91| 一边摸一边做爽爽视频免费| 在线观看日韩欧美| 91成人精品电影| 精品午夜福利视频在线观看一区| 两个人免费观看高清视频| 欧美一级a爱片免费观看看 | 女生性感内裤真人,穿戴方法视频| 咕卡用的链子| 色精品久久人妻99蜜桃| 纯流量卡能插随身wifi吗| 在线av久久热| 午夜福利一区二区在线看| 50天的宝宝边吃奶边哭怎么回事| 极品教师在线免费播放| 亚洲精品一卡2卡三卡4卡5卡| 制服诱惑二区| 久久久国产欧美日韩av| 午夜久久久久精精品| 亚洲中文av在线| 国产精品乱码一区二三区的特点 | 久久欧美精品欧美久久欧美| 精品日产1卡2卡| 岛国视频午夜一区免费看| 色综合婷婷激情| 日韩av在线大香蕉| 国产99白浆流出| 日本vs欧美在线观看视频| 日韩 欧美 亚洲 中文字幕| 久久人妻av系列| 露出奶头的视频| 老熟妇乱子伦视频在线观看| 如日韩欧美国产精品一区二区三区| 婷婷精品国产亚洲av在线| 久久草成人影院| 日本欧美视频一区| 精品午夜福利视频在线观看一区| 色在线成人网| 国产成人一区二区三区免费视频网站| 亚洲中文字幕一区二区三区有码在线看 | 老汉色av国产亚洲站长工具| 国产精品一区二区免费欧美| 亚洲av美国av| 久久热在线av| 黄片小视频在线播放| 久久国产精品人妻蜜桃| 久久中文看片网| 成人18禁高潮啪啪吃奶动态图| 宅男免费午夜| 黑人欧美特级aaaaaa片| 欧美黄色片欧美黄色片| 久久人妻av系列| 深夜精品福利| 夜夜躁狠狠躁天天躁| 亚洲久久久国产精品| xxx96com| www.999成人在线观看| 久久久久久久久免费视频了| 精品乱码久久久久久99久播| 久久热在线av| 一二三四社区在线视频社区8| 国产精品电影一区二区三区| 最近最新中文字幕大全免费视频| 亚洲成人久久性| 色综合欧美亚洲国产小说| www.999成人在线观看| 熟妇人妻久久中文字幕3abv| 两性夫妻黄色片| 精品久久久久久,| av天堂久久9| av在线天堂中文字幕| 欧美成人午夜精品| 国产97色在线日韩免费| 国产91精品成人一区二区三区| 91在线观看av| 黄片大片在线免费观看| 久久国产乱子伦精品免费另类| 精品第一国产精品| 国产亚洲精品久久久久5区| 亚洲精品在线美女| 成人国语在线视频| 国产精品二区激情视频| 国产精品乱码一区二三区的特点 | 精品久久久久久,| 淫妇啪啪啪对白视频| 搡老妇女老女人老熟妇| 亚洲国产欧美日韩在线播放| 一卡2卡三卡四卡精品乱码亚洲| 19禁男女啪啪无遮挡网站| 免费无遮挡裸体视频| 99久久国产精品久久久| 免费av毛片视频| 91在线观看av| 禁无遮挡网站| 欧美在线黄色| 真人做人爱边吃奶动态| 麻豆av在线久日| 人人妻人人澡欧美一区二区 | 亚洲性夜色夜夜综合| 夜夜看夜夜爽夜夜摸| 久久精品国产99精品国产亚洲性色 | 嫁个100分男人电影在线观看| 午夜影院日韩av| 黄色a级毛片大全视频| 日本a在线网址| 老熟妇仑乱视频hdxx| 日本在线视频免费播放| 极品教师在线免费播放| 999久久久精品免费观看国产| 亚洲成国产人片在线观看| 亚洲男人天堂网一区| 757午夜福利合集在线观看| 日本一区二区免费在线视频| 他把我摸到了高潮在线观看| 国产伦一二天堂av在线观看| 麻豆国产av国片精品| 亚洲精品久久成人aⅴ小说| 在线国产一区二区在线| 桃红色精品国产亚洲av| 巨乳人妻的诱惑在线观看| 国产成人免费无遮挡视频| 一级片免费观看大全| 人人妻人人澡欧美一区二区 | 香蕉丝袜av| 色哟哟哟哟哟哟| 午夜久久久在线观看| 黑丝袜美女国产一区| 夜夜看夜夜爽夜夜摸| 精品日产1卡2卡| 午夜福利免费观看在线| 日本黄色视频三级网站网址| 欧美成人免费av一区二区三区| 成人免费观看视频高清| 亚洲熟女毛片儿| 中出人妻视频一区二区| 变态另类丝袜制服| 一二三四在线观看免费中文在| 欧美丝袜亚洲另类 | 男人的好看免费观看在线视频 | 波多野结衣高清无吗| 亚洲情色 制服丝袜| 日本a在线网址| 嫩草影视91久久| 精品久久久久久久久久免费视频| 亚洲av熟女| 午夜免费成人在线视频| 国内精品久久久久精免费| 亚洲精华国产精华精| 日韩成人在线观看一区二区三区|